Clinical Trial Update: Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

A clinical trial evaluating a cyclin B1 peptide-pulsed autologous dendritic cell vaccine for resectable non-small cell lung cancer has been withdrawn. The trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyclin B1 peptide-pulsed autologous dendritic cell vaccine (Cyclin B1 peptide-pulsed autologous dendritic cell vaccine)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Non-small Cell Lung Cancer | NA | Status: WITHDRAWN